OncoCyte Corp
NASDAQ:OCX

Watchlist Manager
OncoCyte Corp Logo
OncoCyte Corp
NASDAQ:OCX
Watchlist
Price: 3.16 USD -1.25% Market Closed
Market Cap: 90.4m USD

Net Margin
OncoCyte Corp

-1 516.1%
Current
-1 769%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 516.1%
=
Net Income
-58.3m
/
Revenue
3.8m

Net Margin Across Competitors

OncoCyte Corp
Glance View

Market Cap
90.4m USD
Industry
Biotechnology

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 110 full-time employees. The company went IPO on 2015-12-30. The firm is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.

OCX Intrinsic Value
4.56 USD
Undervaluation 31%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 516.1%
=
Net Income
-58.3m
/
Revenue
3.8m
What is the Net Margin of OncoCyte Corp?

Based on OncoCyte Corp's most recent financial statements, the company has Net Margin of -1 516.1%.

Back to Top